We are live on ! Find out more
ASMB icon

Assembly Biosciences
ASMB

65 hedge funds and large institutions have $259M invested in Assembly Biosciences in 2017 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,736% more call options, than puts

Call options by funds: $4.16M | Put options by funds: $86K

133% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 12

33% more funds holding

Funds holding: 49 → 65 (+16)

0.28% more ownership

Funds ownership: 5.75% → 6.03% (+0.28%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

14% less capital invested

Capital invested by funds: $301M → $259M (-$42.8M)

18% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 17

Holders
65
Holders Change
+16
Holders Change %
+32.65%
% of All Funds
1.62%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
28
Increased
14
Reduced
17
Closed
12
Calls
$4.16M
Puts
$86K
Net Calls
+$4.07M
Net Calls Change
+$648K

Top Buyers

1
BlackRock
BlackRock
New York
+$12.9M
2
State Street
State Street
Massachusetts
+$4.81M
3
JP Morgan Chase
JP Morgan Chase
New York
+$3.89M
4
Northern Trust
Northern Trust
Illinois
+$3.16M
5
Renaissance Technologies
Renaissance Technologies
New York
+$3.15M

Top Sellers

1
O
OrbiMed
New York
-$8.66M
2
QF
QVT Financial
New York
-$7.1M
3
PA
Perceptive Advisors
New York
-$5.22M
4
Millennium Management
Millennium Management
New York
-$2.54M
5
ACA
Avoro Capital Advisors
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
51
Legal & General Group
United Kingdom
$212K +$240K +852 New
PPA
52
Parametric Portfolio Associates
Washington
$204K +$23.7K +84 +11%
AIG
53
American International Group
New York
$180K +$204K +725 New
NFA
54
Nationwide Fund Advisors
Ohio
$161K +$183K +650 New
FPF
55
FNY Partners Fund
New York
$113K – – –
PCM
56
Prelude Capital Management
New York
$47K +$54.1K +192 New
BNP Paribas Financial Markets
57
BNP Paribas Financial Markets
France
$30.4K +$34.6K +123 New
AIP
58
Ameritas Investment Partners
Nebraska
$25K +$29K +103 New
TRCT
59
Tower Research Capital (TRC)
New York
$20K +$22.5K +80 New
UBS Group
60
UBS Group
Switzerland
$19K -$13.8K -49 -40%
Group One Trading
61
Group One Trading
Illinois
$16K -$141K -500 -88%
Federated Hermes
62
Federated Hermes
Pennsylvania
$10K -$4.22K -15 -26%
Royal Bank of Canada
63
Royal Bank of Canada
Ontario, Canada
$6K – – –
Citigroup
64
Citigroup
New York
$3K +$3.66K +13 New
William Blair & Company
65
William Blair & Company
Illinois
– -$852K -3,404 Closed
LCM
66
Laurion Capital Management
New York
– -$663K -2,167 Closed
Barclays
67
Barclays
United Kingdom
– -$586K -2,080 -100%
SCM
68
Segantii Capital Management
Hong Kong
– -$502K -1,643 Closed
PP
69
PDT Partners
New York
– -$367K -1,200 Closed
DCM
70
Dupont Capital Management
Delaware
– -$344K -1,126 Closed
BCM
71
BlueCrest Capital Management
Jersey
– -$309K -1,012 Closed
GP
72
GLG Partners
United Kingdom
– -$225K -736 Closed
HSBC Holdings
73
HSBC Holdings
United Kingdom
– -$206K -674 Closed
Zurich Cantonal Bank
74
Zurich Cantonal Bank
Switzerland
– -$122K -400 Closed
TDC
75
Thompson Davis & Co
Virginia
– -$80K -260 Closed
1 2
3
4

ASMB Hedge Fund Activity: Q2 2017 in Review

65 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q2 2017, worth a combined $259M — down 14% from $301M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new ASMB positions and 12 closed out — a net gain of 16 holders — while 14 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $12.9M. The largest seller was OrbiMed, cutting an estimated $8.66M.

  • 65 institutional investors held Assembly Biosciences (ASMB) as of Q2 2017, up from 49 in Q1 2017.
  • Funds reported $259M of Assembly Biosciences stock for Q2 2017, down 14% quarter-over-quarter.
  • 28 funds opened new Assembly Biosciences positions in Q2 2017 and 12 closed out, a net change of +16 holders.
  • The largest Assembly Biosciences buyer in Q2 2017 was BlackRock, an estimated $12.9M added.
  • The largest Assembly Biosciences seller in Q2 2017 was OrbiMed, an estimated $8.66M sold.

Based on aggregated 13F filings for Q2 2017.